Literature DB >> 15987683

Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice.

Diana Dominguez1, Jos Tournoy, Dieter Hartmann, Tobias Huth, Kim Cryns, Siska Deforce, Lutgarde Serneels, Ira Espuny Camacho, Els Marjaux, Katleen Craessaerts, Anton J M Roebroek, Michael Schwake, Rudi D'Hooge, Patricia Bach, Ulrich Kalinke, Dieder Moechars, Christian Alzheimer, Karina Reiss, Paul Saftig, Bart De Strooper.   

Abstract

Beta-secretase (BACE1) is the rate-limiting protease for the generation of the amyloid beta-peptide (Abeta) in Alzheimer disease. Mice in which the bace1 gene is inactivated are reported to be healthy. However, the presence of a homologous gene encoding BACE2 raises the possibility of compensatory mechanisms. Therefore, we have generated bace1, bace2, and double knockout mice. We report here that BACE1 mice display a complex phenotype. A variable but significant number of BACE1 offspring died in the first weeks after birth. The surviving mice remained smaller than their littermate controls and presented a hyperactive behavior. Electrophysiologically, subtle alterations in the steady-state inactivation of voltage-gated sodium channels in BACE1-deficient neurons were observed. In contrast, bace2 knockout mice displayed an overall healthy phenotype. However, a combined deficiency of BACE2 and BACE1 enhanced the bace1-/- lethality phenotype. At the biochemical level, we have confirmed that BACE1 deficiency results in an almost complete block of Abeta generation in neurons, but not in glia. As glia are 10 times more abundant in brain compared with neurons, our data indicate that BACE2 could indeed contribute to Abeta generation in the brains of Alzheimer disease and, in particular, Down syndrome patients. In conclusion, our data challenge the general idea of BACE1 as a safe drug target and call for some caution when claiming that no major side effects should be expected from blocking BACE1 activity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15987683     DOI: 10.1074/jbc.M505249200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  140 in total

1.  BACE2 expression increases in human neurodegenerative disease.

Authors:  Christopher J Holler; Robin L Webb; Ashley L Laux; Tina L Beckett; Dana M Niedowicz; Rachel R Ahmed; Yinxing Liu; Christopher R Simmons; Amy L S Dowling; Angela Spinelli; Moshe Khurgel; Steven Estus; Elizabeth Head; Louis B Hersh; M Paul Murphy
Journal:  Am J Pathol       Date:  2011-11-07       Impact factor: 4.307

Review 2.  Physiological functions of the amyloid precursor protein secretases ADAM10, BACE1, and presenilin.

Authors:  Johannes Prox; Andrea Rittger; Paul Saftig
Journal:  Exp Brain Res       Date:  2011-11-27       Impact factor: 1.972

3.  The neural cell adhesion molecules L1 and CHL1 are cleaved by BACE1 protease in vivo.

Authors:  Lujia Zhou; Soraia Barão; Mathias Laga; Katrijn Bockstael; Marianne Borgers; Harry Gijsen; Wim Annaert; Diederik Moechars; Marc Mercken; Kris Gevaert; Kris Gevaer; Bart De Strooper
Journal:  J Biol Chem       Date:  2012-06-12       Impact factor: 5.157

Review 4.  Amyloid-β peptide: Dr. Jekyll or Mr. Hyde?

Authors:  Daniela Puzzo; Ottavio Arancio
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

5.  Secretome protein enrichment identifies physiological BACE1 protease substrates in neurons.

Authors:  Peer-Hendrik Kuhn; Katarzyna Koroniak; Sebastian Hogl; Alessio Colombo; Ulrike Zeitschel; Michael Willem; Christiane Volbracht; Ute Schepers; Axel Imhof; Albrecht Hoffmeister; Christian Haass; Steffen Roßner; Stefan Bräse; Stefan F Lichtenthaler
Journal:  EMBO J       Date:  2012-06-22       Impact factor: 11.598

Review 6.  Inhibition of BACE1 for therapeutic use in Alzheimer's disease.

Authors:  Xiaoyang Luo; Riqiang Yan
Journal:  Int J Clin Exp Pathol       Date:  2010-07-08

7.  Inhibition of beta-secretase in vivo via antibody binding to unique loops (D and F) of BACE1.

Authors:  Lujia Zhou; Lucia Chávez-Gutiérrez; Katrijn Bockstael; Ragna Sannerud; Wim Annaert; Patrick C May; Eric Karran; Bart De Strooper
Journal:  J Biol Chem       Date:  2011-01-05       Impact factor: 5.157

Review 8.  Natural products as a source of Alzheimer's drug leads.

Authors:  Philip Williams; Analia Sorribas; Melanie-Jayne R Howes
Journal:  Nat Prod Rep       Date:  2010-11-12       Impact factor: 13.423

Review 9.  Targeting the β secretase BACE1 for Alzheimer's disease therapy.

Authors:  Riqiang Yan; Robert Vassar
Journal:  Lancet Neurol       Date:  2014-02-17       Impact factor: 44.182

10.  Physiological and behavioral effects of amphetamine in BACE1(-/-) mice.

Authors:  R Madelaine Paredes; E Piccart; E Navaira; D Cruz; M A Javors; W Koek; M J Beckstead; C Walss-Bass
Journal:  Genes Brain Behav       Date:  2015-05-21       Impact factor: 3.449

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.